
Opinion|Videos|August 13, 2026
When Primary OSA Therapy Isn't Enough: Counseling on Residual Sleepiness
Winter opens the discussion by highlighting that millions of Americans with narcolepsy and OSA suffer from undertreated EDS. He sets the stage for understanding the unmet need that solriamfetol addresses.
Advertisement
Episodes in this series

Megan Maroney, PharmD, BCPP, addresses patients who remain sleepy despite adherence to primary OSA therapies like CPAP, noting that these devices may resolve airway obstruction without fully treating residual EDS. She discusses the point at which lingering sleepiness should prompt a conversation about adding pharmacologic treatment.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
Pharmacist Care Gets BP Patients to Goal Faster, Safer
3
Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer
4
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
5

































































































